CDK4 and breast carcinoma: Presently, three CDK4/6 inhibitors (CDK4/6i), palbociclib, ribociclib, and abemaciclib, have gained FDA approval for the treatment of metastatic ER-positive, HER2-negative breast cancer in combination with hormone therapy9–11.